NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests James F. O’MahonyMike PauldenChris McCabe Current Opinion 19 January 2021 Pages: 139 - 146
Modifying NICE’s Approach to Equity Weighting Mike PauldenChristopher McCabe Leading Article 31 January 2021 Pages: 147 - 160
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve Pedram Sendi Practical Application Open access 31 October 2020 Pages: 161 - 169
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Willem J. A. WitloxSabine E. GrimmAntoinette D. I. van Asselt Review Article Open access 04 November 2020 Pages: 171 - 180
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis Nannan LiDennis CornelissenMickaël Hiligsmann Systematic Review Open access 07 October 2020 Pages: 181 - 209
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review Gian Luca Di TannaMichael UrbichGary Globe Systematic Review Open access 30 November 2020 Pages: 211 - 229
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer Katrine WallaceKelly AdamskiAnita Chawla Original Research Article 04 November 2020 Pages: 231 - 241
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies Luis HernandezMalinda O’Donnellfor MSOAC Original Research Article Open access 29 September 2020 Pages: 243 - 256
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs Baudouin StandaertChristophe SauboinMark P. Connolly Original Research Article Open access 25 November 2020 Pages: 257 - 269